XML 60 R40.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details) $ / shares in Units, € in Millions |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Aug. 24, 2017 USD ($) $ / shares shares | Aug. 24, 2017 EUR (€) shares | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Dec. 31, 2015 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2015 USD ($)
Novartis Pharma AG [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Common stock aggregate fair value | $ 4,800,000 |  |  |  |  |  |
Common stock premium | 200,000 |  |  |  |  |  |
Novartis Pharma AG [Member] | Common Stock [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Cash received from sale of shares | $ 5,000,000 |  |  |  |  |  |
Number of shares sold | shares | 539,131 | 539,131 |  |  |  |  |
Sale of stock price per share | $ / shares | $ 9.2742 |  |  |  |  |  |
Common stock closing price | $ / shares | $ 8.93 |  |  |  |  |  |
Novartis Pharma AG [Member] | Les Laboratories Servier [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Repayments of debt | $ 14,300,000 | € 12.0 |  |  |  |  |
Novartis Pharma AG [Member] | XOMA-052 License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement consideration received | 30,000,000 |  |  |  |  |  |
Upfront payment received | 15,700,000 |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | 438,000,000 |  |  |  |  |  |
Revenue recognized under licensing agreement |  |  |  |  |  | $ 0 |
Milestone received under license agreement |  |  |  |  |  | 0 |
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment received | 10,000,000 |  |  |  |  |  |
Novartis Pharma AG [Member] | XOMA-052 License Agreement and IL-1 Target License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
License agreement consideration received | 40,200,000 |  |  |  |  |  |
Upfront payment received | 25,700,000 |  |  |  |  |  |
Common stock premium | 200,000 |  |  |  |  |  |
Novartis Pharma AG [Member] | XOMA-052 License Agreement and IL-1 Target License Agreement [Member] | Les Laboratories Servier [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Repayments of debt | 14,300,000 |  |  |  |  |  |
Novartis Pharma AG [Member] | IL-1 Beta IP License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized under licensing agreement |  |  |  |  |  | 31,900,000 |
Novartis Pharma AG [Member] | Gevokizumab License Agreement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Revenue recognized under licensing agreement |  |  |  |  |  | 8,300,000 |
Novartis International [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Cash received from sale of shares | $ 5,000,000 |  |  |  |  |  |
Number of shares sold | shares | 539,131 | 539,131 |  |  |  |  |
Common stock aggregate fair value | $ 4,800,000 |  |  |  |  |  |
Common stock closing price | $ / shares | $ 8.93 |  |  |  |  |  |
Common stock premium | $ 200,000 |  |  |  |  |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones |  |  |  |  |  | 470,000,000 |
Revenue recognized under licensing agreement |  |  | $ 35,400,000 |  |  |  |
Performance deliverable period for license and regulatory services |  |  |  |  |  |  | 90 days
Performance deliverable period for transfer of materials, process and knowhow |  |  |  |  |  |  | 90 days
Performance deliverables value on stand alone basis |  |  |  |  |  |  | $ 0
Novartis International [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 37,000,000 |  |
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones |  |  |  |  |  | 480,000,000 |
Milestone received under the collaboration agreement |  |  |  | $ 10,000,000 |  | $ 10,000,000 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations. + References No definition available. + Details
Name: | us-gaap_RepaymentsOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate fair value of common stock. + References No definition available. + Details
Name: | xoma_AggregateFairValueOfCommonStock
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Closing stock price per share. + References No definition available. + Details
Name: | xoma_ClosingStockPricePerShare
Namespace Prefix: | xoma_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock premium. + References No definition available. + Details
Name: | xoma_CommonStockPremium
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Eligible milestone payments receivable upon achievement of development regulatory and commercial milestones. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement consideration received. + References No definition available. + Details
Name: | xoma_LicenseAgreementConsiderationReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone received under license agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderLicenseAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Repayment of loan by a customer on behalf of the Company in conjunction with a license agreement. + References No definition available. + Details
Name: | xoma_NonCashRepaymentOfServierLoan
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Performance deliverable period for license and regulatory services + References No definition available. + Details
Name: | xoma_PerformanceDeliverablePeriodForLicenseAndRegulatoryServices
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance deliverable period for transfer of materials, process and knowhow + References No definition available. + Details
Name: | xoma_PerformanceDeliverablePeriodForTransferOfMaterialsProcessAndKnowhow
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance deliverables value on stand alone basis + References No definition available. + Details
Name: | xoma_PerformanceDeliverablesValueOnStandAloneBasis
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Proceeds from upfront payment. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_NovartisPharmaAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LineOfCreditFacilityAxis=xoma_LesLaboratoriesServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementAndIL1TargetLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_IL1BetaIPLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_GevokizumabLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |